CRISPR, the gene-editing technology, has been one of the major breakthroughs in biology in the last two decades. And while ...

CRISPR Therapeutics' (NASDAQ: CRSP) stock may be down by 21% this year so far, but that doesn't mean you should write it off ...

Ngangbam Punita and Snata KaushikPlant disease has always been a nuisance in food production. Since then, it has always been a challenge for plant pathologists to come up with effective and ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $49.49, denoting a -0.2% change from the preceding trading day.

Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end ...

CREME is a virtual laboratory that allows scientists to simulate specific decreases in gene activity. It offers a powerful new tool for identifying and understanding important parts of the genome. And ...

CRISPR Therapeutics has experienced a 21% decline in its stock value this year. Despite this drop, the biotech company ...

News about biofuels sometimes mentions used cooking oil as a feedstock, but if these substances contain animal fat, they can ...

The future of CRISPR involves clinical trials focused on treatment for blood diseases and cancers, cardiovascular disease, ...

Mission Bio explains how single-cell multiomics can help researchers overcome the challenges of heterogeneous editing ...